ZNF280B

Across TCGA pan-cancer cohorts, ZNF280B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF280B data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZNF280B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF280B expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

SCLC, BLCA, and BRCA are the cancer types where ZNF280B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	36	view →
BLCA	OS	Median	All	0.017	0.720	<.001	24	view →
BRCA	OS	Median	III,IV	0.211	0.833	<.001	22	view →
SKCM	OS	Median	III,IV	0.257	0.708	.004	20	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.921	0.627	.029	6	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF280B–SCLC (OS)

Open the SCLC breakdown →